We are live on ! Find out more
RA

Royce & Associates Portfolio holdings

AUM $12.4B
1-Year Est. Return 64.17%
This Fund
S&P 500
This Quarter Est. Return
-2.2%
1 Year Est. Return
+64.17%
3 Year Est. Return
+130.04%
5 Year Est. Return
+162.55%
10 Year Est. Return
+785.5%
AUM
$13.4B
AUM Growth
-$1.18B
Cap. Flow
-$624M
Cap. Flow %
-4.67%
Top 10 Hldgs %
7.94%
Holding
1,057
New
56
Increased
305
Reduced
416
Closed
75

Top Buys

Rank Stock Value
1
IOSP icon
Innospec
IOSP
+$25.1M
2
HAE icon
Haemonetics
HAE
+$24.2M
3
CALX icon
Calix
CALX
+$22.2M
4
MXCT icon
MaxCyte
MXCT
+$21.3M
5
FRG
Franchise Group, Inc.
FRG
+$21.3M

Sector Composition

Rank Sector Weight
1 Industrials 25.4%
2 Technology 20.93%
3 Financials 15.39%
4 Consumer Discretionary 13.63%
5 Materials 7.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
OSG
851
Octave Specialty Group
OSG
$218M
$759K 0.01%
53,000
GPI icon
852
Group 1 Automotive
GPI
$3.32B
$759K 0.01%
+4,040
New +$686K
ARKO icon
853
ARKO Corp
ARKO
$507M
$754K 0.01%
+74,700
New +$673K
HNI icon
854
HNI Corp
HNI
$3.38B
$744K 0.01%
20,259
+14,600
+258% +$565K
NOA
855
North American Construction
NOA
$363M
$736K 0.01%
50,000
SCSC icon
856
Scansource
SCSC
$1.18B
$732K 0.01%
21,028
+12,556
+148% +$386K
LVO icon
857
LiveOne
LVO
$54.6M
$724K 0.01%
24,200
-24,000
-50% -$831K
IMBI
858
DELISTED
iMedia Brands, Inc. Class A Common Stock
IMBI
$711K 0.01%
+123,577
New +$793K
LFCR icon
859
Lifecore Biomedical
LFCR
$156M
$697K 0.01%
75,610
CYXT
860
DELISTED
Cyxtera Technologies, Inc. Class A Common Stock
CYXT
$697K 0.01%
+75,300
New +$704K
HLSQ
861
Tessera Defense and Homeland Security Inc.
HLSQ
$2.89M
$691K 0.01%
119
-70
-37% -$542K
ADEA icon
862
Adeia
ADEA
$2.95B
$690K 0.01%
138,363
+98,299
+245% +$530K
SSTK icon
863
Shutterstock
SSTK
$186M
$685K 0.01%
6,045
-8,233
-58% -$890K
GCO icon
864
Genesco
GCO
$380M
$680K 0.01%
11,775
+7,363
+167% +$438K
GAN
865
DELISTED
GAN Ltd
GAN
$665K 0.01%
44,700
PATI
866
DELISTED
Patriot Transportation Holding, Inc. Common Stock
PATI
$662K 0.01%
55,764
BRC icon
867
Brady Corp
BRC
$4.08B
$633K ﹤0.01%
+12,479
New +$657K
VIRT icon
868
Virtu Financial
VIRT
$5.37B
$632K ﹤0.01%
25,857
+885
+4% +$22.5K
KRMD icon
869
KORU Medical Systems
KRMD
$146M
$624K ﹤0.01%
218,900
+25,600
+13% +$84.7K
PETQ
870
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
$624K ﹤0.01%
25,000
-72,000
-74% -$2.17M
GVA icon
871
Granite Construction
GVA
$5.28B
$616K ﹤0.01%
15,566
+31
+0.2% +$1.23K
GASS icon
872
StealthGas
GASS
$354M
$615K ﹤0.01%
229,664
ATTO
873
DELISTED
Atento S.A.
ATTO
$613K ﹤0.01%
21,742
OSUR icon
874
OraSure Technologies
OSUR
$224M
$611K ﹤0.01%
54,007
-11,957
-18% -$131K
NXGN
875
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
$606K ﹤0.01%
42,983
+14,432
+51% +$224K

Similar funds

Royce & Associates's Q3 2021 Portfolio in Review

As of Q3 2021, Royce & Associates held 1,057 positions worth $13.4B, down 8.1% from $14.6B the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.

Royce & Associates withdrew a net $624M in Q3 2021, closing 75 positions and reducing 416 holdings. Its most notable exit was SmileDirectClub, Inc. Class A Common Stock, an estimated $32.3M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 25% of assets, up from 25% a quarter earlier, followed by Technology and Financials.

Against the trend, Royce & Associates opened a new position in Calix worth $23.8M.

  • Royce & Associates's largest Q3 2021 buy was Calix: 480,993 shares worth $23.8M.
  • Royce & Associates added most to Innospec in Q3 2021, an estimated $25.1M increase.
  • Royce & Associates's biggest Q3 2021 reduction was Kulicke & Soffa, cutting an estimated $37.4M.
  • Royce & Associates fully exited SmileDirectClub, Inc. Class A Common Stock in Q3 2021, selling an estimated $32.3M.
  • Royce & Associates's ten largest holdings make up 7.9% of its $13.4B portfolio in Q3 2021.
  • Royce & Associates opened 56 new positions and closed 75 in Q3 2021.
  • Royce & Associates's portfolio value fell 8.1% quarter-over-quarter to $13.4B.

Based on Royce & Associates's 13F filing for Q3 2021, filed 10 Nov 2021.